Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.00
  • Today's Change-0.21 / -3.38%
  • Shares traded187.89k
  • 1 Year change-51.32%
  • Beta0.9172
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

  • Revenue in USD (TTM)167.14m
  • Net income in USD-25.03m
  • Incorporated2020
  • Employees297.00
  • Location
    Immatics NVPaul Ehrlich-Strasse 15TUEBINGEN 72076GermanyDEU
  • Phone+49 70 715397700
  • Websitehttps://immatics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MeiraGTx Holdings PLC34.51m-167.33m692.75m372.00--20.68--20.08-2.31-2.310.46920.41680.1294--5.7990,572.18-62.76-30.69-77.23-38.4126.25---484.90-428.391.51-21.240.6895--137.4220.15-75.89---11.21--
Amylyx Pharmaceuticals Inc-607.00k-218.86m738.09m123.00--3.66-----3.10-3.10-0.00842.26-0.0019-----4,934.96-68.70-51.56-82.97-60.70-------118.26----0.00---77.06127.75-712.42------
Tango Therapeutics Inc40.99m-132.26m743.58m155.00--4.45--18.14-1.21-1.210.37521.540.1205----264,458.10-38.87---43.95-------322.67-283.69----0.00--15.17---28.07------
Maze Therapeutics Inc-100.00bn-100.00bn747.18m125.00--2.56----------6.67----------------------------0.00------103.39------
Immatics NV167.14m-25.03m754.83m297.00--1.21--4.52-0.2537-0.25371.495.120.2227--39.06562,760.10-3.33-20.25-3.96-28.38-----14.97-79.55----0.0331--188.6053.23116.08--49.13--
Vir Biotechnology Inc20.86m-577.65m758.93m408.00--0.7262--36.38-4.22-4.220.15257.560.0135----51,129.90-37.25-4.58-40.25-5.3496.23---2,769.04-13.27----0.00---13.9055.7715.14---3.97--
Nuvation Bio Inc10.96m-606.38m764.43m273.00--1.81--69.77-2.34-2.340.03671.230.0198--2.2549,804.55-109.69-33.42-116.94-34.4916.29---5,534.21-11,132.319.01--0.0134-------649.24---24.47--
Iovance Biotherapeutics Inc212.68m-375.36m781.41m838.00--1.02--3.67-1.23-1.230.69962.300.23164.005.98253,793.60-40.88-50.14-46.04-56.8421.72---176.49-1,097.643.64--0.0013--13,698.99--16.18--9.86--
AnaptysBio Inc111.87m-140.62m783.87m136.00--23.83--7.01-4.84-4.843.811.120.2703--8.96822,588.30-33.97-19.96-37.42-21.08-----125.70-200.59----0.00--432.0362.7311.24---14.96--
Kalvista Pharmaceuticals Inc0.00-183.45m799.76m270.00--8.35-----3.69-3.690.001.920.00----0.00-75.47-49.86-87.73-54.21------------0.5261-------44.85--33.39--
Trevi Therapeutics Inc0.00-47.35m802.28m26.00--6.87-----0.4486-0.44860.000.99560.00----0.00-51.03-45.07-54.61-51.11------------0.00-------64.84--31.21--
Sionna Therapeutics Inc0.00-66.32m808.80m48.00--2.30-----1.55-1.550.007.98------0.00--------------------0.00-------30.52------
Niagen Bioscience Inc107.93m14.11m815.66m104.0060.1214.6754.757.560.17220.17221.350.70561.593.4219.701,037,740.0020.83-23.1229.66-35.2062.5160.7313.07-15.713.12--0.0002--19.1816.56273.15---26.37--
Geron Corp116.29m-139.02m821.62m229.00--3.06--7.07-0.2109-0.21090.17580.42120.2227--6.53507,829.70-26.62-47.39-32.39-60.6597.88---119.54-871.156.97-48.820.3068--32,386.92178.455.19--10.49--
Syndax Pharmaceuticals Inc43.72m-331.20m832.08m270.00--3.87--19.03-3.86-3.860.50922.500.0739--3.01161,933.30-55.96-32.19-63.79-35.1159.49---757.52-440.065.75--0.6162----73.25-52.25------
Data as of Jul 18 2025. Currency figures normalised to Immatics NV's reporting currency: US Dollar USD

Institutional shareholders

59.34%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 31 Mar 202514.68m12.30%
Perceptive Advisors LLCas of 31 Mar 20259.38m7.86%
Suvretta Capital Management LLCas of 31 Mar 20259.14m7.65%
Wellington Management Co. LLPas of 31 Mar 20258.20m6.87%
Baker Bros. Advisors LPas of 31 Mar 20257.28m6.10%
Vestal Point Capital LPas of 31 Mar 20257.19m6.03%
RTW Investments LPas of 31 Mar 20256.91m5.79%
Morgan Stanley & Co. LLCas of 31 Mar 20253.08m2.58%
Cowen Financial Products LLCas of 31 Mar 20252.97m2.49%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 20251.99m1.67%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.